Skip to content
Pharmacology advanced

Peptide Bond Geometry in Drug Design

How peptide bond geometry influences drug design through bioisosteres, peptidomimetics, and conformational constraint strategies.

By Wikipept Community | 3 min read
drug-design peptidomimetics bioisosteres conformational-constraint pharmacology

Peptide Bond Geometry in Drug Design

Understanding peptide bond geometry is crucial for designing effective peptide-based therapeutics. The spatial arrangement of atoms in peptide bonds directly influences drug potency, selectivity, and pharmacokinetic properties.

Peptide Bond Geometry Fundamentals

Key geometric features of peptide bonds:

Planarity: The peptide bond is planar due to resonance between carbonyl oxygen and nitrogen lone pair. This restricts rotation and creates distinct conformations.

Cis-trans isomerism: Most peptide bonds are trans, but cis forms occur, especially with proline residues. The energy difference (~2-8 kcal/mol) affects drug binding and stability.

Dihedral angles: The phi (φ) and psi (ψ) angles define backbone conformation. These angles determine secondary structure and three-dimensional shape.

Bioisosteres in Peptide Drug Design

Bioisosteres replace peptide bonds while maintaining biological activity:

Amide bond replacements:

  • Thioamides: Replace oxygen with sulfur, similar geometry but different electronics
  • Reduced amides: CH₂NH replacement increases metabolic stability
  • Fluoroalkenes: Planar, bioisosteric for trans-amide bonds

Ring constraints:

  • Lactams: Cyclized bioisosteres that restrict conformation
  • Spirocycles: Rigid frameworks that mimic peptide geometry
  • Heterocycles: Pyrrolidinones, piperazinones as amide mimics

Peptidomimetics Strategies

Peptidomimetics are molecules designed to mimic peptide structure and function:

Type 1: Secondary structure mimetics

  • Alpha-helix mimetics using terphenyl scaffolds
  • Beta-turn mimetics using cyclic peptides
  • Beta-sheet mimetics using peptoids

Type 2: Backbone modifications

  • N-methylation to reduce hydrogen bonding
  • D-amino acid incorporation for protease resistance
  • Peptide bond surrogates for improved stability

Type 3: Side chain modifications

  • Conformational restriction of side chains
  • Prodrug approaches for improved delivery
  • Bioisosteric replacements for metabolic stability

Conformational Constraint

Constraining peptide conformation improves drug properties:

Cyclization strategies:

  • Lactam bridges: Side chain to backbone cyclization
  • Disulfide bonds: Cysteine-cysteine linkages
  • Hydrocarbon staples: Conformational locking via hydrocarbon bridges
  • Click chemistry: Triazole formation for macrocyclization

Benefits of constraint:

  • Increased potency: Pre-organized binding conformation
  • Improved selectivity: Reduced off-target interactions
  • Enhanced stability: Resistance to proteolysis
  • Better pharmacokinetics: Improved oral bioavailability

Design Principles

When designing peptide-based drugs:

  1. Start with natural peptide: Understand the binding mode
  2. Identify key pharmacophores: Determine essential interactions
  3. Apply bioisosteres: Replace metabolically labile bonds
  4. Add constraint: Restrict to bioactive conformation
  5. Optimize properties: Balance potency, selectivity, and ADME

Practical Learning Tip

Mnemonic: “BPC for Drug Design” - Remember the three key concepts: Bioisosteres (replacing bonds), Peptidomimetics (mimicking structure), Constraint (restricting flexibility). These form the foundation of peptide drug design.

Case Studies

Cyclosporine A: A cyclic peptide with N-methylated amino acids, demonstrating how constraint and modification can create an orally available immunosuppressant.

Enfuvirtide: An HIV fusion inhibitor that uses conformational constraint to maintain helical structure.

Gonadotropin-releasing hormone analogs: Modified peptides with improved half-life and potency through various constraint strategies.

Understanding peptide bond geometry and its application in drug design is essential for developing effective peptide therapeutics with improved properties.